Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

about

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity.

P2860

Q36171531-5B65D165-FB50-41A5-B26B-EBA0F42BE32B Q37409633-2752E444-365F-435E-B6C2-35CFB52E3D42

P2860

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Item

http://www.wikidata.org/entity/Q36109866

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@ast

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@en

type

Item

label

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@ast

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@en

prefLabel

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@ast

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@en

P1476

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

@en

P2093

Ester Carreón-Guarnizo

http://www.w3.org/2001/XMLSchema#string

Jose Eustasio Meca-Lallana

http://www.w3.org/2001/XMLSchema#string

Rocío Hernández-Clares

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Non pharmacological interventions for spasticity in multiple sclerosis

Anti-spasticity agents for multiple sclerosis

Multiple sclerosis: side effects of interferon beta therapy and their management

Treatments for spasticity and pain in multiple sclerosis: a systematic review

Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review

Antidepressant exacerbation of spasticity

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.

P304

e00367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1002/BRB3.367

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2015-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280916372

http://www.w3.org/2001/XMLSchema#string

P698

26445705

http://www.w3.org/2001/XMLSchema#string

P921

peptide

multiple sclerosis

P932

4589813

http://www.w3.org/2001/XMLSchema#string

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

about

P2860

P2860

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P5875

P698

P921

P932